Skip to main content
Access every election story that matters
Enjoy unlimited digital access
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
per week
for 24 weeks
// //

Moderna Inc NASDAQ: MRNA-Q

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 406.87
Day High 442.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.


Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.



A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
- PR Newswire - PRF - Fri Sep 17, 8:45AM CDT
PR Newswire - PRF - CMTX
Fri Sep 17, 8:45AM CDT
/PRNewswire/ --   -  Using the same technology as their Covid-19 shot, scientists behind the and (NASDAQ:AZN) are getting closer to developing a , based on promising animal studies results. Based on the rapidly accelerating development of Covid-19 tech,  in the field of oncology to keep pace, with a COTA survey reporting  of cancer patients and their close family members reporting disappointment or frustration with the progress of investigational cancer treatments. Thankfully, isn't the only group in this fight, with several  coming from other biotech firms, such as (CSE:BIOV) (OTCQB:BVAXF), (NASDAQ:BNTX), (NASDAQ:CVAC), and (NASDAQ:MRNA).
NetworkNewsAudio Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment
- MENAFN - Thu Sep 16, 2:07PM CDT
Thu Sep 16, 2:07PM CDT
(MENAFN - Investor Brand Network) Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That's a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, the no. 1 and no. 5 leading causes of death in the nation each year. To that point, the CDC names hypertension as a primary or contributing cause in nearly half a million deaths annually in the U.S. Hypertension treatment options vary tremendously from meditation to conventional drugs, with what looks to be a promising new innovation on the horizon from . Lexaria is proving that its proprietary DehydraTECH(TM) technology repeatedly delivers strong therapeutic responses, without the side effects of today's drugs. Lexaria is looking to throw its hat into the ring with majors in the market today that are making billions of dollars by treating high blood pressure and other leading causes of death, including , , and .
Moderna Announces Health Canada Approves its COVID-19 Vaccine
- Business Wire - Thu Sep 16, 11:13AM CDT
Business Wire - CMTX
Thu Sep 16, 11:13AM CDT
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX(TM) (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years of age and older.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 362.80 +14.49% increase
on 08/30/21
Period Open:401.86
Price movement based on the high, low and last over the given period.
464.85 -10.64% decrease
on 09/10/21
+13.51 (+3.36%) increase
since 08/17/21
3-Month 194.51 +113.55% increase
on 06/18/21
Period Open:202.47
Price movement based on the high, low and last over the given period.
497.49 -16.51% decrease
on 08/10/21
+212.90 (+105.15%) increase
since 06/17/21
52-Week 63.64 +552.69% increase
on 09/24/20
Period Open:67.89
Price movement based on the high, low and last over the given period.
497.49 -16.51% decrease
on 08/10/21
+347.48 (+511.83%) increase
since 09/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies